Mostashari's company raises $30M in funding

Aledade, the accountable care company founded by former national coordinator Farzad Mostashari, MD, MSc, last year, has secured $30 million in a second round of funding.

Mostashari said the company, with a mission of making it easy, profitable and low risk for smaller physician practices to transition to pay for value, will use funds to expand service offerings and engage private health plans.

The funding round was led by ARCH Venture Partners, and includes an additional investment from Series A investor Venrock.

Aledade also is working on prevention-focused applications and practice-centered software platforms for partner practices; initiating value-based arrangements with commercial health plans and hiring additional team members to help primary care practices deliver better care and better health for patients at lower cost.

"There is a revolution happening in healthcare, and we are finding that doctors across the country are ready to embrace this change, but need a partner to help them get there. Aledade is that partner," said Mostashari in a release about the new funding. "We’re helping independent physicians achieve better outcomes for their patients--and be compensated for it. The demand for our services has been overwhelming. This funding will help us reach more doctors, and continue to provide them an expanding array of services to better run their business and care for their patients."

Since its founding, Aledade has expanded from New York, Maryland, Delaware and Arkansas to West Virginia, Louisiana, Kansas, Mississippi and Florida and plans to triple the number of covered Medicare beneficiaries in Aledade ACOs from approximately 25,000 last year, to more than 75,000 in over 100 physician practices by the end of this year, Mostashari said.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.